Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Caroverine→

Caroverine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
23465-76-1
Molecular formula
C22H27N3O2
Molecular weight
365.5 g/mol
Drug class
Smooth-muscle spasmolyticcalcium-channel and phosphodiesterase inhibitor properties
Mechanism of action
Relaxes smooth muscle through calcium-channel blocking and phosphodiesterase-inhibitory effects. Proposed additional effects on glutamatergic signalling have been described, but the clinical mechanism is not fully established.
Indications / reported uses
  • Used in some countries for symptomatic relief of visceral smooth-muscle spasm and selected otological or vestibular complaints; indications and evidence vary by jurisdiction and product

Sources: NLM MeSH — Caroverine · PubMed — Caroverine pharmacology and clinical use · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Smooth-muscle spasmolytic; calcium-channel and phosphodiesterase inhibitor properties

Mechanism of action

Relaxes smooth muscle through calcium-channel blocking and phosphodiesterase-inhibitory effects. Proposed additional effects on glutamatergic signalling have been described, but the clinical mechanism is not fully established.

General use cases

  • Used in some countries for symptomatic relief of visceral smooth-muscle spasm and selected otological or vestibular complaints; indications and evidence vary by jurisdiction and product

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Caroverine Environmental Risk Assessment (ERA) (the Caroverine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.